KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells $74,793.02 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the sale, the insider now owns 94,199 shares of the company’s stock, valued at $872,282.74. This represents a 7.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

KalVista Pharmaceuticals Stock Up 8.8 %

NASDAQ KALV opened at $10.15 on Friday. The business’s 50-day moving average price is $11.04 and its 200 day moving average price is $11.99. The firm has a market cap of $438.63 million, a P/E ratio of -2.88 and a beta of 0.92. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.39 and a 52-week high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. As a group, analysts anticipate that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current year.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Large investors have recently bought and sold shares of the company. Barclays PLC increased its stake in shares of KalVista Pharmaceuticals by 418.5% during the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock worth $778,000 after acquiring an additional 54,257 shares during the period. Geode Capital Management LLC increased its position in KalVista Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company’s stock worth $9,624,000 after purchasing an additional 24,713 shares during the period. Zimmer Partners LP raised its stake in shares of KalVista Pharmaceuticals by 52.6% during the 3rd quarter. Zimmer Partners LP now owns 95,704 shares of the specialty pharmaceutical company’s stock worth $1,108,000 after buying an additional 33,000 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of KalVista Pharmaceuticals by 40.3% in the 3rd quarter. Wellington Management Group LLP now owns 117,923 shares of the specialty pharmaceutical company’s stock valued at $1,366,000 after buying an additional 33,900 shares during the period. Finally, State Street Corp boosted its stake in shares of KalVista Pharmaceuticals by 68.1% in the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after buying an additional 515,179 shares in the last quarter.

Analysts Set New Price Targets

Several brokerages have commented on KALV. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Monday, October 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $32.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).